Glaucoma Aqueous Shunt Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

Glaucoma Aqueous Shunt Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

Glaucoma Aqueous Shunt Market Overview

The glaucoma aqueous shunt market is an essential segment of the global ophthalmology medical devices market, driven by the increasing prevalence of glaucoma and the growing demand for effective surgical treatments. Aqueous shunts, used to control intraocular pressure in patients with glaucoma, play a crucial role in managing the disease, particularly in cases where other treatments, such as medications and laser therapies, have failed. As the global population ages and the incidence of glaucoma rises, the market for these devices is expected to grow significantly.

Market Size

The glaucoma aqueous shunt market is projected to experience steady growth, with an estimated compound annual growth rate (CAGR) ranging from 6% to 8% during the forecast period. This growth is driven by increasing awareness of glaucoma, the rise in surgeries to treat the disease, and technological advancements in the design of aqueous shunts that offer enhanced safety and effectiveness.

Market Share & Trends Analysis

By Product Type

The market for glaucoma aqueous shunts is segmented based on the types of drainage systems offered, each catering to specific medical needs and preferences:

• Trabecular Meshwork-Schlemm Canal Drainage: This segment is expected to account for the largest market share, with a projected CAGR of 7% to 9%. These drainage systems are commonly used in glaucoma surgeries as they provide a reliable method to regulate intraocular pressure by bypassing the trabecular meshwork. The growth of this segment is supported by the increasing preference for minimally invasive surgical options and the effectiveness of trabecular meshwork-Schlemm canal drainage systems.
• Subconjunctival Drainage: The subconjunctival drainage segment is expected to grow at a CAGR of 5% to 7%, driven by its use in both primary and secondary glaucoma surgeries. These systems are popular in cases where trabecular drainage is not suitable, offering a viable alternative to more complex glaucoma surgeries.
• Others: The "Others" segment, which includes novel drainage systems and less commonly used types, is projected to grow at a moderate rate of 4% to 6%. This segment is fueled by innovations in glaucoma treatment technologies and the introduction of new shunt designs aimed at improving long-term surgical outcomes.

By Application

Glaucoma aqueous shunts are used in various healthcare settings, each with its unique growth dynamics:

• Hospitals: The hospital segment is expected to hold the largest share of the market, with a CAGR of 6% to 8%. Hospitals remain the primary venue for glaucoma surgeries due to their specialized equipment, trained surgical teams, and ability to handle complex procedures. This segment's growth is closely linked to the increasing volume of glaucoma surgeries performed in hospital settings.
• Ophthalmology Clinics: Ophthalmology clinics are projected to experience moderate growth, with a CAGR of 5% to 7%. As more patients seek specialized glaucoma treatment in outpatient settings, the demand for glaucoma aqueous shunts in these clinics will continue to rise, driven by the adoption of advanced surgical techniques and the increasing preference for less invasive treatments.
• Others: This category, which includes research institutions and specialty treatment centers, is expected to grow at a CAGR of 4% to 6%. This growth is largely driven by ongoing research into glaucoma treatments and the emergence of novel aqueous shunt designs aimed at improving patient outcomes and minimizing complications.

By Key Players

Several major players are currently dominating the glaucoma aqueous shunt market. These companies are key contributors to the development, production, and distribution of innovative glaucoma shunt devices:

• AbbVie: AbbVie is a significant player in the glaucoma market, offering advanced aqueous shunt devices that have been proven effective in managing intraocular pressure in glaucoma patients.
• Santen Pharmaceutical: Santen is well-known for its focus on ophthalmic treatments, including glaucoma management, and offers a range of aqueous shunts for different glaucoma types.
• Johnson & Johnson: Johnson & Johnson, through its subsidiary, has introduced several advanced glaucoma aqueous shunt systems aimed at providing better long-term pressure control with fewer complications.
• Advanced Ophthalmic Innovations (AOI): AOI focuses on providing innovative solutions in glaucoma surgery, including state-of-the-art aqueous shunts that have enhanced drainage capacity and safety features.
• New World Medical: New World Medical is known for its innovative glaucoma shunt devices, especially those designed for trabecular meshwork-Schlemm canal drainage, which are widely used in glaucoma surgeries.
• Nova Eye Medical: Nova Eye Medical specializes in novel glaucoma shunt solutions and is recognized for its work in improving the design and efficacy of drainage systems.
• Glaukos Corp: Glaukos is a market leader in the glaucoma space, particularly with its micro-invasive glaucoma surgical (MIGS) devices, which are used in aqueous shunt procedures to reduce intraocular pressure with minimal invasiveness.
• Alcon: Alcon offers a wide range of glaucoma treatments, including aqueous shunt devices that focus on reducing surgical risks and improving patient outcomes.
• iSTAR Medical: iSTAR Medical is known for its innovative glaucoma products, including aqueous shunt devices designed to improve intraocular pressure management in patients with complex glaucoma conditions.

By Region

The glaucoma aqueous shunt market is geographically diverse, with various regions exhibiting different growth patterns:

• North America: North America holds a dominant market share and is expected to grow at a CAGR of 6% to 8%, driven by high healthcare spending, advanced medical facilities, and a large population of glaucoma patients requiring surgical intervention.
• Europe: The European market is projected to grow at a CAGR of 5% to 7%, supported by growing investments in ophthalmic healthcare and increasing awareness of glaucoma treatments.
• Asia-Pacific: The Asia-Pacific region is expected to experience the highest growth, with a CAGR of 8% to 10%, due to a large and aging population, rising healthcare access, and growing awareness of glaucoma management in countries like China and India.
• Latin America and Middle East & Africa: These regions are anticipated to see moderate growth, with a CAGR of 4% to 6%, driven by improvements in healthcare infrastructure and increasing access to advanced glaucoma treatments.

Segment Forecasts (2025-2030)

Growth in Key Segments

• Trabecular Meshwork-Schlemm Canal Drainage: This segment is expected to see steady growth at a CAGR of 7% to 9%, supported by its effectiveness in controlling intraocular pressure and its widespread use in glaucoma surgeries.
• Subconjunctival Drainage: The subconjunctival drainage segment is projected to grow at a CAGR of 5% to 7%, as it is an important alternative treatment option for more complex glaucoma cases.